{"ticker": {"uuid": "e91e7cba-6110-45b1-91f5-c910aa03b42c", "symbol": "ESPR", "name": "Esperion Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake", "summary": "Wasatch Advisors has reported a 0.7% beneficial ownership stake in Esperion Therapeutics (ESPR), amounting to 1,930,185 shares. This filing, a Schedule 13G/A, indicates that Wasatch Advisors holds sole voting and dispositive power over these shares, qualifying it as an \"Ownership", "url": "https://www.stocktitan.net/sec-filings/ESPR/schedule-13g-a-esperion-therapeutics-inc-amended-passive-investment-d-795f69e75403.html", "source_name": "Stock Titan", "published_at": "2026-07-14T21:16:37", "published_display": "14 Jul 2026 21:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Esperion Therapeutics, Inc. \u2013 DUS:0ET", "summary": "This article provides financial information for Esperion Therapeutics, Inc. (DUS:0ET) on TradingView, focusing specifically on its enterprise value to revenue forward metric. The content highlights a specific financial period, value, and change for the company, accessible through", "url": "https://www.tradingview.com/symbols/DUS-0ET/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T09:11:17", "published_display": "14 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PFE6265887 Bond Risk Profile", "summary": "This page provides a risk profile for the Esperion Therapeutics, Inc. bond (PFE6265887) with a 5.75% coupon maturing on June 15, 2030. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help users evaluate t", "url": "https://www.tradingview.com/symbols/FINRA-PFE6265887/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-14T03:11:17", "published_display": "14 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Esperion Therapeutics Inc For: 13 July By Investing.com", "summary": "This article announces the filing of Form 4 for Esperion Therapeutics Inc., dated July 13. Form 4 is a document filed with the SEC by company insiders detailing changes in their ownership of the company's stock. The article mentions the stock symbol ESPR and its slight price chan", "url": "https://ng.investing.com/news/stock-market-news/form-4-esperion-therapeutics-inc-for-13-july-93CH-2597429", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T22:11:17", "published_display": "13 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PFE6265887 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Esperion Therapeutics, Inc. bond PFE6265887, which has a 5.75% coupon rate and matures on June 15, 2030. The bond has an outstanding amount of $100 million and a face value of $1,000. Esperion Therapeutics is a biopharmaceutical company f", "url": "https://www.tradingview.com/symbols/FINRA-PFE6265887/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-13T21:12:53", "published_display": "13 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) director exits holdings in $3.16-per-share cash and CVR merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTVg5WGNvdC1LZUUtUWg1VkhkN2VoVEpVUnMtdkVJczRsQmhBRDVVQXhrT19uY2Rxb2hyUVNSZ0czQ3Fwd2tZUFNOUkl4cThSU1VEZTh6MHRHdGMyaXlHSDZ0Nkp0SzdxWkZLTGdqNVNHZFFYNmFyYm0zSzI4bzJYZ1ZmblBHVlJBSEM1SzVTV2FibHJXTWRnUkRTR0g3eFFYNG5STndOU3AtRmIwYVVRVXZPdjlTYlB5MV93?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:05:05+00:00", "published_display": "13 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) CCO swaps 424,536 RSUs for $3.16 cash plus CVRs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOUjl2Zm5kdFRJalBzdWlfcUEtZUhjcmFHQ21OazZpdlBzeXZUajlJamlTVXVIUjVMVE1KQlJkNldRYUNYcG1qYzJxNmlYcWxNRWROSW84dTFNVXk4ZmduaGFNYjl6UGNpY2U4bG9xeElNeVZSQjVvOTV5Q2d4T2M5MTdDY0lvUm9vS2pxeHRUaFFxVUhMMzhyeFdPR2U2TndaMVVTUHBmQ0VxMm00eVJzWU9vZGk2MGJLdDI0?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:04:44+00:00", "published_display": "13 Jul 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) CLO equity cashed out at $3.16 plus CVRs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOW9ZRzJnWEtZUURISnVuOFd5cEZ5UndidU9rUm9US0hrOGVnM0ItaVo1eVJrdWxVVnA1dkxPZ0c4S0xic3hjTVhwMThZTm5hU0RIUG9YRFlFOGVQcVNoZUtsazZ0VUMyQVJPVTFHVlNkMkE2MUtXeHZjbEtLU3d0a1VrbUZGTmQ5cHhjVmVSZi1EaG1KdjgyV255dnExT3NwVHl0dWhzMWxEblJqNWFTVW9qT0lJUFl0Wk1z?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:04:23+00:00", "published_display": "13 Jul 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) CEO exits equity in cash-and-CVR merger payout", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPcWVzRUlWU0FvVHFzMVllVlA5LXBLVllKemhjdEgtVFpHUzJlQzlzVnl2dzFNZURaZ3pvbkUxN1ktY3VzVTlGamVIdTloU0ZfNXNSRk9oUVRIWTlLVlU4MURWYU5xNm9DYkF5MTBQQl96bXNZU3BNY0E1MFBZRElDOEVDMVFsVThTejVtU3FxZDU0WnNUSGtpY0lJN3p2MEpGdmpKbjg1cF80ZGVBb2VGRHczTjdQcUt2eGtF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:03:33+00:00", "published_display": "13 Jul 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs in merger", "summary": "Esperion Therapeutics director Seth H. Z. Fischer cashed out his equity holdings in the company as part of a merger where Esperion became a wholly-owned subsidiary of Essence Parent Inc. He disposed of 141,023 common shares, 79,873 restricted stock units, and several in-the-money", "url": "https://www.stocktitan.net/sec-filings/ESPR/form-4-esperion-therapeutics-inc-insider-trading-activity-c8fa22f8d3ef.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:12:53", "published_display": "13 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity", "summary": "Esperion Therapeutics' CFO Benjamin Halladay disposed of his equity, including 705,410 shares of common stock and various stock options, due to the company's merger with Essence Parent Inc. The merger converted each share of common stock and in-the-money options into $3.16 cash p", "url": "https://www.stocktitan.net/sec-filings/ESPR/form-4-esperion-therapeutics-inc-insider-trading-activity-3fb150726bc8.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:12:53", "published_display": "13 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) director converts shares and options into $3.16 cash and CVRs", "summary": "Esperion Therapeutics director Jay Shepard reported dispositions of shares and stock options following the closing of a merger with Essence Parent Inc. and Essence MergerCo Inc. His 164,472 common shares were converted into $3.16 cash per share plus one contingent value right (CV", "url": "https://www.stocktitan.net/sec-filings/ESPR/form-4-esperion-therapeutics-inc-insider-trading-activity-d7eef5e0064a.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:11:17", "published_display": "13 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs", "summary": "Esperion Therapeutics director Robert E. Hoffman reported the disposition of common stock and stock options due to the company's merger, where it became a wholly owned subsidiary of Essence Parent Inc. His 85,153 shares were converted into $3.16 cash per share plus one", "url": "https://www.stocktitan.net/sec-filings/ESPR/form-4-esperion-therapeutics-inc-insider-trading-activity-37ff9e41835e.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:11:17", "published_display": "13 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[POSASR] Esperion Therapeutics, Inc. SEC Filing", "summary": "Esperion Therapeutics, Inc. has filed a Post-Effective Amendment No. 1 to its Form S-3ASR registration statement (No. 333-258397) to deregister unsold securities. This action follows the company's merger with Essence MergerCo Inc., a wholly-owned subsidiary of Essence Parent Inc.", "url": "https://www.stocktitan.net/sec-filings/ESPR/posasr-esperion-therapeutics-inc-sec-filing-383c5aea063a.html", "source_name": "Stock Titan", "published_at": "2026-07-13T16:12:53", "published_display": "13 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[POS AM] Esperion Therapeutics, Inc. SEC Filing", "summary": "Esperion Therapeutics, Inc. has filed a post-effective amendment to several S-3 and S-3MEF registration statements to deregister unsold securities. This action follows the company's merger with MergerCo, a wholly-owned subsidiary of Essence Parent Inc., which became effective on ", "url": "https://www.stocktitan.net/sec-filings/ESPR/pos-am-esperion-therapeutics-inc-sec-filing-48849c113911.html", "source_name": "Stock Titan", "published_at": "2026-07-13T16:12:53", "published_display": "13 Jul 2026 16:12", "sentiment": "negative", "sentiment_pct": 20, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ESPR Stock Falls After Esperion\u2019s Mixed Q4 \u2014 Retail Remains Unfazed, Eyes \u2018Massive\u2019 Upcoming Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOaVJjMll2RlBORG1lQUd3SFlmMkFyQl9RQTF3TEZ2SjdkREZYUVBwVnA4WkI3cGxlQzk4cTA2LU81UnpGZFlfN1FMOG9hLU5TTW9CZmF2bEpPSmtrbjNxcWp4NFNvekxpY3g4eUxWNHRTQXdxdjR3UWd5WFY1S3BuT0p6MmxCUXdzUzhkOUQ5dGVRcWNlSWppVjRieTZsRDZTM1hUYTNnLWJrcVYtbFdsd00zaW5mbklUd0Nlc3RB?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T13:40:09+00:00", "published_display": "13 Jul 2026 13:40", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics Announced Transfer or Voluntary Withdrawal of Listing", "summary": "Esperion Therapeutics (ESPR) announced its decision to delist its common stock from Nasdaq following a merger. The company has requested Nasdaq to file a Form 25 for delisting and deregistration and plans to file a Form 15 to suspend its SEC reporting obligations.", "url": "https://www.tradingview.com/news/tradingview:286b280791524:0-esperion-therapeutics-announced-transfer-or-voluntary-withdrawal-of-listing/", "source_name": "TradingView", "published_at": "2026-07-13T13:41:42", "published_display": "13 Jul 2026 13:41", "sentiment": "negative", "sentiment_pct": 5, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) moves to remove its Nasdaq listing", "summary": "Esperion Therapeutics, Inc. (ESPR) is removing its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. This delisting was certified by Nasdaq and affects the company's common stock, meaning less vis", "url": "https://www.stocktitan.net/sec-filings/ESPR/25-nse-esperion-therapeutics-inc-sec-filing-14b807fbbb8a.html", "source_name": "Stock Titan", "published_at": "2026-07-13T13:41:41", "published_display": "13 Jul 2026 13:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 2000 Value-Dynamic Index", "summary": "Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been dropped from the Russell 2000 Value-Dynamic Index. This article also details the company's profile as a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, including its prod", "url": "https://www.marketscreener.com/news/esperion-therapeutics-inc-nasdaqgm-espr-dropped-from-russell-2000-value-dynamic-index-ce7f5edfdd8bf020", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T15:41:42", "published_display": "10 Jul 2026 15:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 3000 Value Benchmark", "summary": "Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been removed from the Russell 3000 Value Benchmark, alongside several other Russell indices. The biopharmaceutical company specializes in developing cardiometabolic and rare/orphan disease therapies, including medications like NEXLE", "url": "https://www.marketscreener.com/news/esperion-therapeutics-inc-nasdaqgm-espr-dropped-from-russell-3000-value-benchmark-ce7f5edfdd8bff20", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T15:39:18", "published_display": "10 Jul 2026 15:39", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger", "summary": "Esperion Therapeutics' stockholders have approved the company's merger agreement with Essence Parent and Essence MergerCo in a virtual meeting held on July 8, 2026. The approval means Essence MergerCo will merge with Esperion, with Esperion becoming a wholly-owned subsidiary of E", "url": "https://es.tradingview.com/news/marketbeat:2675ca5eb094b:0-esperion-therapeutics-clears-key-hurdle-as-stockholders-approve-essence-merger/", "source_name": "TradingView", "published_at": "2026-07-10T15:09:13", "published_display": "10 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell Small Cap Comp Value Index", "summary": "Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been removed from the Russell Small Cap Comp Value Index, as well as several other Russell indices including the Russell 2000 Growth, Russell 2500 Growth, and Russell 3000 indices. The company is a biopharmaceutical firm focused on ", "url": "https://www.marketscreener.com/news/esperion-therapeutics-inc-nasdaqgm-espr-dropped-from-russell-small-cap-comp-value-index-ce7f5edfdd8bf126", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T03:40:25", "published_display": "10 Jul 2026 03:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 2000 Growth Benchmark", "summary": "Esperion Therapeutics Inc. (NasdaqGM:ESPR) has been removed from several Russell Growth and Value benchmarks, including the Russell 2000 Growth Benchmark. This move affects the company's inclusion in various small-cap and broader Russell indices. Esperion Therapeutics is a biopha", "url": "https://www.marketscreener.com/news/esperion-therapeutics-inc-nasdaqgm-espr-dropped-from-russell-2000-growth-benchmark-ce7f5edfdd8bff2c", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T03:10:38", "published_display": "10 Jul 2026 03:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) investors back merger with Essence Parent in special meeting vote", "summary": "Esperion Therapeutics (ESPR) stockholders have approved the merger with Essence Parent Inc. at a special meeting held on July 8, 2026. This approval, with 135,326,793 votes in favor, moves forward the transaction for Esperion to become a wholly owned subsidiary of Essence Parent.", "url": "https://www.stocktitan.net/sec-filings/ESPR/8-k-esperion-therapeutics-inc-reports-material-event-3f4a183a11c7.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:39:41", "published_display": "08 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics stock leans on its cholesterol portfolio.", "summary": "Esperion Therapeutics, a Nasdaq-listed company, is judged by the market on the performance of its cholesterol-lowering medicines, commercial execution, and prescription trends. The company's core business focuses on non-statin LDL-C lowering therapies, Nexletol and Nexlizet. Succ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/esperion-therapeutics-stock-leans-on-its-cholesterol-portfolio/69716140", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:10:52", "published_display": "07 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) AGM 2026 Summary", "summary": "Esperion Therapeutics held its 2026 AGM, marking the CEO's sixth year and confirming a quorum with over 257 million shares. Two Class I directors were nominated for re-election, and shareholders approved all four proposals, including the election of directors, executive compensat", "url": "https://quartr.com/events/esperion-therapeutics-espr-agm-2026_onVSw34C", "source_name": "Quartr", "published_at": "2026-07-07T14:39:41", "published_display": "07 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) Stock Forecast & Analyst Ratings", "summary": "This article provides a stock forecast and analyst ratings for Esperion Therapeutics (ESPR). It includes detailed financial analysis, price targets from various analysts, and a summary of recent performance and market sentiment for the company.", "url": "https://www.moomoo.com/stock/ESPR-US/forecast?chain_id=Name1K9-3FXPhg.1kvd400&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A33,%22f%22%3A%22mm%2Fnews%2Fpost%2F35886807%22%7D", "source_name": "Moomoo", "published_at": "2026-07-05T02:10:52", "published_display": "05 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ESPR - Esperion Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Esperion Therapeutics Inc (ESPR), including its stock performance, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, short interest, and volatility metrics,", "url": "https://finviz.com/stock?t=ESPR&ta=1&p=d&ty=ocv&b=1&ov=list_strike&s=3.5", "source_name": "Finviz", "published_at": "2026-07-04T14:10:18", "published_display": "04 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics focuses on cholesterol treatments as investors watch long-term growth", "summary": "Esperion Therapeutics, a biopharmaceutical company, centers its strategy on developing oral non-statin cholesterol therapies for patients who cannot tolerate statins or need additional lipid-lowering support. The company aims to differentiate itself by offering an oral alternativ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/esperion-therapeutics-focuses-on-cholesterol-treatments-as-investors-watch/69679130", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T11:21:34", "published_display": "03 Jul 2026 11:21", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Esperion Therapeutics, Inc. \u2013 NASDAQ:ESPR", "summary": "This article provides financial information for Esperion Therapeutics, Inc. (ESPR) on TradingView, focusing on its enterprise value to forward revenue. It highlights the company's stock market presence on Nasdaq within the pharmaceuticals sector, offering an overview of its finan", "url": "https://www.tradingview.com/symbols/NASDAQ-ESPR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:39:47", "published_display": "26 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Esperion Therapeutics, Inc. \u2013 NASDAQ:ESPR", "summary": "The article focuses on the \"Price to earnings forward\" metric for Esperion Therapeutics, Inc. (NASDAQ: ESPR). It briefly presents this specific financial data point within a larger financial platform context, implying it's a key piece of information for investors. However, no act", "url": "https://www.tradingview.com/symbols/NASDAQ-ESPR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:27", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc. Actuals & Estimates (DUS:0ET)", "summary": "This article provides an overview of Esperion Therapeutics, Inc. (0ET) on the Dusseldorf Stock Exchange, including its financial actuals and analyst estimates. It covers key financial metrics like earnings, revenue, net income, and EBITDA, as well as stock performance data and an", "url": "https://www.tradingview.com/symbols/DUS-0ET/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:27", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst Downgrades", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPejBxandLS2JaaV9WTjNmWTVIZVBRYkE4eS1FMEpISnhocVlnMEpFVFBGazFRMjhYY0lHOHNQNUtfMWNkd3p0RS1VMnVaVEkwM2Q1YVpKbnc4c2xvLTN3MmphVS1ERGdFbXBma1A2ZDl6OTJzTExvemM3RU80al8wZE9xVV9ielp2djkyQ0I1YWZnbzRZU096OEVORjI4NU5xcUZrbA?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion (ESPR) CEO sells shares to cover RSU taxes, retains 2.12M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPT3ZzVzJKYUo3NTRDaFF6OFNwM0hDVVhCTHd0V1lEazRBbXdaOXQ3NVVtTkpfTEhuQWMxNjBWNXhOcHFqaXludWw3RHVuN1p1WllUWGpyWUtDbkNON1F2RHRPNzNBbEk4dDJtSFFhaFN6azlNbFZGY0hGOVE0QkF4dnZrMnlQVUpMeERua1NEOHczNG9aelpIM2RPNzNJcmFfUEFMbzVhSUpudVliYTdZTjJSbkpCcG5RVDVF?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion (NASDAQ: ESPR) gains HSR clearance ahead merger vote", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPTUVIb3lyVWRScUVxZzhmMkdBOGlTOW5tcHVRVlhQSkpGbzdaUFU1N2hpSUZKbWdXZEpYcmY3eEpYMEpDYk4ySmxFZHpvaWdVSjRjcUQtWDY3ME5QZ1hOLUlKRktkS1FwRl9SX19RVTl5NjUzT0hRQV81RzVYNFVaYXVkVjBrY0RtT2NDMTJhVWlDb3I1WVNTRmpfbnRvdDVWbW1YWUVyUzZKM05VUnNoeGI1WlM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/esperion-presents-data-clear-outcomes-120000138.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T12:00:00+00:00", "published_display": "26 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/esperion-announces-inducement-grants-under-203000828.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:30:00+00:00", "published_display": "14 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026", "summary": "", "url": "https://finance.yahoo.com/news/esperion-announces-two-analyses-supporting-120000745.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T12:00:00+00:00", "published_display": "13 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Downgrades Esperion Therapeutics to Hold From Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/needham-downgrades-esperion-therapeutics-hold-110821924.html", "source_name": "MT Newswires", "published_at": "2026-05-05T11:08:21+00:00", "published_display": "05 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Downgrades Esperion Therapeutics to Neutral From Overweight, Adjusts Price Target to $3.16 From $9", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/piper-sandler-downgrades-esperion-therapeutics-112522147.html", "source_name": "MT Newswires", "published_at": "2026-05-04T11:25:22+00:00", "published_display": "04 May 2026 11:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCHIMED to buy Esperion (Nasdaq: ESPR) for $3.16 per share plus CVRs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOOFV5cVd0azRxb1FBdTB3djhFQmJnNmpudU5iME9Ib0lMdEdaclVRNVl4YjIwZ2FDZGFiSkQ1dzdKU1ExeGFuVWo2UVE5VkUwNF9RdEN1TnprY2pzeEVmLWhsMktxOHUzNDJCbE51YWFLOWFGZDlpTzVWNzJtaWx1akpUSTJ0Y2E1YlVpZFZRT2MxZlA2SnNOZU9xVzk1Z0Y4eE1BdHVuNXE1SW1JZWZJSDR1WWo?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc. ($ESPR) President and CEO 2025 Pay Revealed | ESPR Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxORld1QkYxVkN0RkFtanFxcnVWWGxXQzRCdTQxbGJ1cjJ4akMzeVdPbHJUa3BCa203T1BSbUtaUXk2QzBySXp0cUQ0MkloVVBPZE9UM2h4NU5uSjZ4WnFCMzc4cVIwUWtNZG4tZnY2NVVfeWV3SDVMN0lqc1NvNzFVZWFTcEFKb2JqZHUwa3RRRWhFTFF2OElHZ2lmQWlmUjBZcmdWeEJINlRlQmhaZ1lZOGJR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNbzZqNVdldUl4LVI2WUZ6eURnNUFwV2xGbWNTaHl4RHFsVmVkNERfcldxbm56SmpBZHJCVDUxS21WdklTQmo2X244R0FtYTV2NGMtTFRpRExkMW50NU9lU0JMQ3otZndHQThhM0VXZHhfNTRYVjVGTW9jYVRLbVFLUlZtUlZXXzJPV21fbFREQjJ1WnR1UVNSU2NYM3hsOEdKYVhUV3Z3?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA reiterates Esperion Therapeutics stock Underperform rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQWGMxNlIyV3luZUpGWDJPbWlHYzlYVElaT3VzSkJWZHRINTYwMUV0V0FIaldNZEtTakFHQU1RVy1KMmxCZnV1c0Z5LWRlT1J6YlVHZ1NHeWNRMU1rNzlQWl9HQkhxdy1YZVdVd29pY1JFa0dKLTBOREF5dHhfZWFGMnNyLXBKczlzZ0R5VnZDNzd0ZDdMUFY2SmFfQkl6N0xCejlZZGZqcFFwZlM5aVFrZVEwdnhYaDZFb0tkSnNHaDE?oc=5", "source_name": "Investing.com", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breaking News: Massive Guideline NEWS for Esperion Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQZTVueVV6YkIzdWxvcnIwaFRZSkFYTDFNNy15WFhJTzFlOXJfU1g5TlNJdE1rMlMweWstSGtHNlhVd3dNWE9QQUs4NE9jSGFHWHJHR3dXNlQ5R2VJZDZqTVliRVg5cmJxVDlMTFRTckRRdU44bmlfRDN0bHVZYjA2UlJHYlRoS1lrWWluVlAtTVJwNkl5eTAzd2tmU2tmNTJQNllmVlhJZEY1Q003UW1jYklXak45STQ?oc=5", "source_name": "Moomoo", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Esperion Therapeutics Stock Sinking Premarket Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOMW0zVHl4d0RoYTR1S29nUlQ0bFc3cVJ1UElSU3hacEk5blp3T25OOTRqcjJURlpHTU42S1VNRG1ELU5HcGdVeDFkWXB5OG1sOEVTUV9UWTB4LTRGUm5xZUV2NTM4UndaV2kxZWNneWhETlp1eURwcklEWUZRc05QcE10LUhKVGVCMENubHN2UnRQTTlhVDNBUURHWXBkeEd4MTJMWmVWTWpjdVo5XzNnRnVfQkV2NEZ3dkQ1Qnd3OA?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc. (ESPR) Stock Price Today: $3.19", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE8zd0dNS3dneVNaYU11ZGVPWHdBaG1Tb0pGdHNHNy1QS0ZRQjNTRjRKRXNqdGtVdk4yQ2xiVkJsd3NiZE9WT295a251OHZ6bEdaVEJVMHBmNA?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T00:25:52+00:00", "published_display": "13 Jan 2026 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxNZlZ5eVc5OFpxQWlnYnN4Vk9waEZ1RERsby14SWFDNVJCejdNZzVxU1UzNjRmeERVc25OM3ZkRUhjcGQ2OG5FMGdnem9sTjdtcXZwaWhmajY4a19rT2NpQTVTMFZDUUFsZEwyMlBtY1pwXy1BU21tYnJ5anZmLWFsa0xscEpGd0lFUnhEaFlJVkl4ZXIwTWdhX1VtRUVkWmM0bmtNaWVRYW9nMkpWeHFsMTFQRFJySTFWeGVGWDhsaU1QWjh2Vk9GeFBMc2FvYlpqM1N2alBqbVpmUXN0bkx1dVhBVDBza1RCMGtfb1VySVEzNXJJODlBZDNIQUk5NjBPOTFwUGVxeTRDVTBhSDgyWHJjeXh3c0U?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR): Evaluating Valuation After $75 Million Equity Raise and Recent Share Price Volatility", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake", "summary": "Wasatch Advisors has reported a 0.7% beneficial ownership stake in Esperion Therapeutics (ESPR), amounting to 1,930,185 shares. This filing, a Schedule 13G/A, indicates that Wasatch Advisors holds sole voting and dispositive power over these shares, qualifying it as an \"Ownership", "url": "https://www.stocktitan.net/sec-filings/ESPR/schedule-13g-a-esperion-therapeutics-inc-amended-passive-investment-d-795f69e75403.html", "source_name": "Stock Titan", "published_at": "2026-07-14T21:16:37", "published_display": "14 Jul 2026 21:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Esperion Therapeutics, Inc. \u2013 DUS:0ET", "summary": "This article provides financial information for Esperion Therapeutics, Inc. (DUS:0ET) on TradingView, focusing specifically on its enterprise value to revenue forward metric. The content highlights a specific financial period, value, and change for the company, accessible through", "url": "https://www.tradingview.com/symbols/DUS-0ET/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T09:11:17", "published_display": "14 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PFE6265887 Bond Risk Profile", "summary": "This page provides a risk profile for the Esperion Therapeutics, Inc. bond (PFE6265887) with a 5.75% coupon maturing on June 15, 2030. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help users evaluate t", "url": "https://www.tradingview.com/symbols/FINRA-PFE6265887/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-14T03:11:17", "published_display": "14 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Esperion Therapeutics Inc For: 13 July By Investing.com", "summary": "This article announces the filing of Form 4 for Esperion Therapeutics Inc., dated July 13. Form 4 is a document filed with the SEC by company insiders detailing changes in their ownership of the company's stock. The article mentions the stock symbol ESPR and its slight price chan", "url": "https://ng.investing.com/news/stock-market-news/form-4-esperion-therapeutics-inc-for-13-july-93CH-2597429", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T22:11:17", "published_display": "13 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PFE6265887 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Esperion Therapeutics, Inc. bond PFE6265887, which has a 5.75% coupon rate and matures on June 15, 2030. The bond has an outstanding amount of $100 million and a face value of $1,000. Esperion Therapeutics is a biopharmaceutical company f", "url": "https://www.tradingview.com/symbols/FINRA-PFE6265887/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-13T21:12:53", "published_display": "13 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) director exits holdings in $3.16-per-share cash and CVR merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTVg5WGNvdC1LZUUtUWg1VkhkN2VoVEpVUnMtdkVJczRsQmhBRDVVQXhrT19uY2Rxb2hyUVNSZ0czQ3Fwd2tZUFNOUkl4cThSU1VEZTh6MHRHdGMyaXlHSDZ0Nkp0SzdxWkZLTGdqNVNHZFFYNmFyYm0zSzI4bzJYZ1ZmblBHVlJBSEM1SzVTV2FibHJXTWRnUkRTR0g3eFFYNG5STndOU3AtRmIwYVVRVXZPdjlTYlB5MV93?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:05:05+00:00", "published_display": "13 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) CCO swaps 424,536 RSUs for $3.16 cash plus CVRs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOUjl2Zm5kdFRJalBzdWlfcUEtZUhjcmFHQ21OazZpdlBzeXZUajlJamlTVXVIUjVMVE1KQlJkNldRYUNYcG1qYzJxNmlYcWxNRWROSW84dTFNVXk4ZmduaGFNYjl6UGNpY2U4bG9xeElNeVZSQjVvOTV5Q2d4T2M5MTdDY0lvUm9vS2pxeHRUaFFxVUhMMzhyeFdPR2U2TndaMVVTUHBmQ0VxMm00eVJzWU9vZGk2MGJLdDI0?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:04:44+00:00", "published_display": "13 Jul 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) CLO equity cashed out at $3.16 plus CVRs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOW9ZRzJnWEtZUURISnVuOFd5cEZ5UndidU9rUm9US0hrOGVnM0ItaVo1eVJrdWxVVnA1dkxPZ0c4S0xic3hjTVhwMThZTm5hU0RIUG9YRFlFOGVQcVNoZUtsazZ0VUMyQVJPVTFHVlNkMkE2MUtXeHZjbEtLU3d0a1VrbUZGTmQ5cHhjVmVSZi1EaG1KdjgyV255dnExT3NwVHl0dWhzMWxEblJqNWFTVW9qT0lJUFl0Wk1z?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:04:23+00:00", "published_display": "13 Jul 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) CEO exits equity in cash-and-CVR merger payout", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPcWVzRUlWU0FvVHFzMVllVlA5LXBLVllKemhjdEgtVFpHUzJlQzlzVnl2dzFNZURaZ3pvbkUxN1ktY3VzVTlGamVIdTloU0ZfNXNSRk9oUVRIWTlLVlU4MURWYU5xNm9DYkF5MTBQQl96bXNZU3BNY0E1MFBZRElDOEVDMVFsVThTejVtU3FxZDU0WnNUSGtpY0lJN3p2MEpGdmpKbjg1cF80ZGVBb2VGRHczTjdQcUt2eGtF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:03:33+00:00", "published_display": "13 Jul 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs in merger", "summary": "Esperion Therapeutics director Seth H. Z. Fischer cashed out his equity holdings in the company as part of a merger where Esperion became a wholly-owned subsidiary of Essence Parent Inc. He disposed of 141,023 common shares, 79,873 restricted stock units, and several in-the-money", "url": "https://www.stocktitan.net/sec-filings/ESPR/form-4-esperion-therapeutics-inc-insider-trading-activity-c8fa22f8d3ef.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:12:53", "published_display": "13 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity", "summary": "Esperion Therapeutics' CFO Benjamin Halladay disposed of his equity, including 705,410 shares of common stock and various stock options, due to the company's merger with Essence Parent Inc. The merger converted each share of common stock and in-the-money options into $3.16 cash p", "url": "https://www.stocktitan.net/sec-filings/ESPR/form-4-esperion-therapeutics-inc-insider-trading-activity-3fb150726bc8.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:12:53", "published_display": "13 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) director converts shares and options into $3.16 cash and CVRs", "summary": "Esperion Therapeutics director Jay Shepard reported dispositions of shares and stock options following the closing of a merger with Essence Parent Inc. and Essence MergerCo Inc. His 164,472 common shares were converted into $3.16 cash per share plus one contingent value right (CV", "url": "https://www.stocktitan.net/sec-filings/ESPR/form-4-esperion-therapeutics-inc-insider-trading-activity-d7eef5e0064a.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:11:17", "published_display": "13 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs", "summary": "Esperion Therapeutics director Robert E. Hoffman reported the disposition of common stock and stock options due to the company's merger, where it became a wholly owned subsidiary of Essence Parent Inc. His 85,153 shares were converted into $3.16 cash per share plus one", "url": "https://www.stocktitan.net/sec-filings/ESPR/form-4-esperion-therapeutics-inc-insider-trading-activity-37ff9e41835e.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:11:17", "published_display": "13 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[POSASR] Esperion Therapeutics, Inc. SEC Filing", "summary": "Esperion Therapeutics, Inc. has filed a Post-Effective Amendment No. 1 to its Form S-3ASR registration statement (No. 333-258397) to deregister unsold securities. This action follows the company's merger with Essence MergerCo Inc., a wholly-owned subsidiary of Essence Parent Inc.", "url": "https://www.stocktitan.net/sec-filings/ESPR/posasr-esperion-therapeutics-inc-sec-filing-383c5aea063a.html", "source_name": "Stock Titan", "published_at": "2026-07-13T16:12:53", "published_display": "13 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[POS AM] Esperion Therapeutics, Inc. SEC Filing", "summary": "Esperion Therapeutics, Inc. has filed a post-effective amendment to several S-3 and S-3MEF registration statements to deregister unsold securities. This action follows the company's merger with MergerCo, a wholly-owned subsidiary of Essence Parent Inc., which became effective on ", "url": "https://www.stocktitan.net/sec-filings/ESPR/pos-am-esperion-therapeutics-inc-sec-filing-48849c113911.html", "source_name": "Stock Titan", "published_at": "2026-07-13T16:12:53", "published_display": "13 Jul 2026 16:12", "sentiment": "negative", "sentiment_pct": 20, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ESPR Stock Falls After Esperion\u2019s Mixed Q4 \u2014 Retail Remains Unfazed, Eyes \u2018Massive\u2019 Upcoming Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOaVJjMll2RlBORG1lQUd3SFlmMkFyQl9RQTF3TEZ2SjdkREZYUVBwVnA4WkI3cGxlQzk4cTA2LU81UnpGZFlfN1FMOG9hLU5TTW9CZmF2bEpPSmtrbjNxcWp4NFNvekxpY3g4eUxWNHRTQXdxdjR3UWd5WFY1S3BuT0p6MmxCUXdzUzhkOUQ5dGVRcWNlSWppVjRieTZsRDZTM1hUYTNnLWJrcVYtbFdsd00zaW5mbklUd0Nlc3RB?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T13:40:09+00:00", "published_display": "13 Jul 2026 13:40", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics Announced Transfer or Voluntary Withdrawal of Listing", "summary": "Esperion Therapeutics (ESPR) announced its decision to delist its common stock from Nasdaq following a merger. The company has requested Nasdaq to file a Form 25 for delisting and deregistration and plans to file a Form 15 to suspend its SEC reporting obligations.", "url": "https://www.tradingview.com/news/tradingview:286b280791524:0-esperion-therapeutics-announced-transfer-or-voluntary-withdrawal-of-listing/", "source_name": "TradingView", "published_at": "2026-07-13T13:41:42", "published_display": "13 Jul 2026 13:41", "sentiment": "negative", "sentiment_pct": 5, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) moves to remove its Nasdaq listing", "summary": "Esperion Therapeutics, Inc. (ESPR) is removing its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. This delisting was certified by Nasdaq and affects the company's common stock, meaning less vis", "url": "https://www.stocktitan.net/sec-filings/ESPR/25-nse-esperion-therapeutics-inc-sec-filing-14b807fbbb8a.html", "source_name": "Stock Titan", "published_at": "2026-07-13T13:41:41", "published_display": "13 Jul 2026 13:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 2000 Value-Dynamic Index", "summary": "Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been dropped from the Russell 2000 Value-Dynamic Index. This article also details the company's profile as a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, including its prod", "url": "https://www.marketscreener.com/news/esperion-therapeutics-inc-nasdaqgm-espr-dropped-from-russell-2000-value-dynamic-index-ce7f5edfdd8bf020", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T15:41:42", "published_display": "10 Jul 2026 15:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 3000 Value Benchmark", "summary": "Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been removed from the Russell 3000 Value Benchmark, alongside several other Russell indices. The biopharmaceutical company specializes in developing cardiometabolic and rare/orphan disease therapies, including medications like NEXLE", "url": "https://www.marketscreener.com/news/esperion-therapeutics-inc-nasdaqgm-espr-dropped-from-russell-3000-value-benchmark-ce7f5edfdd8bff20", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T15:39:18", "published_display": "10 Jul 2026 15:39", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger", "summary": "Esperion Therapeutics' stockholders have approved the company's merger agreement with Essence Parent and Essence MergerCo in a virtual meeting held on July 8, 2026. The approval means Essence MergerCo will merge with Esperion, with Esperion becoming a wholly-owned subsidiary of E", "url": "https://es.tradingview.com/news/marketbeat:2675ca5eb094b:0-esperion-therapeutics-clears-key-hurdle-as-stockholders-approve-essence-merger/", "source_name": "TradingView", "published_at": "2026-07-10T15:09:13", "published_display": "10 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell Small Cap Comp Value Index", "summary": "Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been removed from the Russell Small Cap Comp Value Index, as well as several other Russell indices including the Russell 2000 Growth, Russell 2500 Growth, and Russell 3000 indices. The company is a biopharmaceutical firm focused on ", "url": "https://www.marketscreener.com/news/esperion-therapeutics-inc-nasdaqgm-espr-dropped-from-russell-small-cap-comp-value-index-ce7f5edfdd8bf126", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T03:40:25", "published_display": "10 Jul 2026 03:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 2000 Growth Benchmark", "summary": "Esperion Therapeutics Inc. (NasdaqGM:ESPR) has been removed from several Russell Growth and Value benchmarks, including the Russell 2000 Growth Benchmark. This move affects the company's inclusion in various small-cap and broader Russell indices. Esperion Therapeutics is a biopha", "url": "https://www.marketscreener.com/news/esperion-therapeutics-inc-nasdaqgm-espr-dropped-from-russell-2000-growth-benchmark-ce7f5edfdd8bff2c", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T03:10:38", "published_display": "10 Jul 2026 03:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) investors back merger with Essence Parent in special meeting vote", "summary": "Esperion Therapeutics (ESPR) stockholders have approved the merger with Essence Parent Inc. at a special meeting held on July 8, 2026. This approval, with 135,326,793 votes in favor, moves forward the transaction for Esperion to become a wholly owned subsidiary of Essence Parent.", "url": "https://www.stocktitan.net/sec-filings/ESPR/8-k-esperion-therapeutics-inc-reports-material-event-3f4a183a11c7.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:39:41", "published_display": "08 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics stock leans on its cholesterol portfolio.", "summary": "Esperion Therapeutics, a Nasdaq-listed company, is judged by the market on the performance of its cholesterol-lowering medicines, commercial execution, and prescription trends. The company's core business focuses on non-statin LDL-C lowering therapies, Nexletol and Nexlizet. Succ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/esperion-therapeutics-stock-leans-on-its-cholesterol-portfolio/69716140", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:10:52", "published_display": "07 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) AGM 2026 Summary", "summary": "Esperion Therapeutics held its 2026 AGM, marking the CEO's sixth year and confirming a quorum with over 257 million shares. Two Class I directors were nominated for re-election, and shareholders approved all four proposals, including the election of directors, executive compensat", "url": "https://quartr.com/events/esperion-therapeutics-espr-agm-2026_onVSw34C", "source_name": "Quartr", "published_at": "2026-07-07T14:39:41", "published_display": "07 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) Stock Forecast & Analyst Ratings", "summary": "This article provides a stock forecast and analyst ratings for Esperion Therapeutics (ESPR). It includes detailed financial analysis, price targets from various analysts, and a summary of recent performance and market sentiment for the company.", "url": "https://www.moomoo.com/stock/ESPR-US/forecast?chain_id=Name1K9-3FXPhg.1kvd400&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A33,%22f%22%3A%22mm%2Fnews%2Fpost%2F35886807%22%7D", "source_name": "Moomoo", "published_at": "2026-07-05T02:10:52", "published_display": "05 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ESPR - Esperion Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Esperion Therapeutics Inc (ESPR), including its stock performance, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, short interest, and volatility metrics,", "url": "https://finviz.com/stock?t=ESPR&ta=1&p=d&ty=ocv&b=1&ov=list_strike&s=3.5", "source_name": "Finviz", "published_at": "2026-07-04T14:10:18", "published_display": "04 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics focuses on cholesterol treatments as investors watch long-term growth", "summary": "Esperion Therapeutics, a biopharmaceutical company, centers its strategy on developing oral non-statin cholesterol therapies for patients who cannot tolerate statins or need additional lipid-lowering support. The company aims to differentiate itself by offering an oral alternativ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/esperion-therapeutics-focuses-on-cholesterol-treatments-as-investors-watch/69679130", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T11:21:34", "published_display": "03 Jul 2026 11:21", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Esperion Therapeutics, Inc. \u2013 NASDAQ:ESPR", "summary": "This article provides financial information for Esperion Therapeutics, Inc. (ESPR) on TradingView, focusing on its enterprise value to forward revenue. It highlights the company's stock market presence on Nasdaq within the pharmaceuticals sector, offering an overview of its finan", "url": "https://www.tradingview.com/symbols/NASDAQ-ESPR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:39:47", "published_display": "26 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Esperion Therapeutics, Inc. \u2013 NASDAQ:ESPR", "summary": "The article focuses on the \"Price to earnings forward\" metric for Esperion Therapeutics, Inc. (NASDAQ: ESPR). It briefly presents this specific financial data point within a larger financial platform context, implying it's a key piece of information for investors. However, no act", "url": "https://www.tradingview.com/symbols/NASDAQ-ESPR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:27", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc. Actuals & Estimates (DUS:0ET)", "summary": "This article provides an overview of Esperion Therapeutics, Inc. (0ET) on the Dusseldorf Stock Exchange, including its financial actuals and analyst estimates. It covers key financial metrics like earnings, revenue, net income, and EBITDA, as well as stock performance data and an", "url": "https://www.tradingview.com/symbols/DUS-0ET/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:27", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst Downgrades", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPejBxandLS2JaaV9WTjNmWTVIZVBRYkE4eS1FMEpISnhocVlnMEpFVFBGazFRMjhYY0lHOHNQNUtfMWNkd3p0RS1VMnVaVEkwM2Q1YVpKbnc4c2xvLTN3MmphVS1ERGdFbXBma1A2ZDl6OTJzTExvemM3RU80al8wZE9xVV9ielp2djkyQ0I1YWZnbzRZU096OEVORjI4NU5xcUZrbA?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion (ESPR) CEO sells shares to cover RSU taxes, retains 2.12M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPT3ZzVzJKYUo3NTRDaFF6OFNwM0hDVVhCTHd0V1lEazRBbXdaOXQ3NVVtTkpfTEhuQWMxNjBWNXhOcHFqaXludWw3RHVuN1p1WllUWGpyWUtDbkNON1F2RHRPNzNBbEk4dDJtSFFhaFN6azlNbFZGY0hGOVE0QkF4dnZrMnlQVUpMeERua1NEOHczNG9aelpIM2RPNzNJcmFfUEFMbzVhSUpudVliYTdZTjJSbkpCcG5RVDVF?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion (NASDAQ: ESPR) gains HSR clearance ahead merger vote", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPTUVIb3lyVWRScUVxZzhmMkdBOGlTOW5tcHVRVlhQSkpGbzdaUFU1N2hpSUZKbWdXZEpYcmY3eEpYMEpDYk4ySmxFZHpvaWdVSjRjcUQtWDY3ME5QZ1hOLUlKRktkS1FwRl9SX19RVTl5NjUzT0hRQV81RzVYNFVaYXVkVjBrY0RtT2NDMTJhVWlDb3I1WVNTRmpfbnRvdDVWbW1YWUVyUzZKM05VUnNoeGI1WlM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/esperion-presents-data-clear-outcomes-120000138.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T12:00:00+00:00", "published_display": "26 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/esperion-announces-inducement-grants-under-203000828.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:30:00+00:00", "published_display": "14 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026", "summary": "", "url": "https://finance.yahoo.com/news/esperion-announces-two-analyses-supporting-120000745.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T12:00:00+00:00", "published_display": "13 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Downgrades Esperion Therapeutics to Hold From Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/needham-downgrades-esperion-therapeutics-hold-110821924.html", "source_name": "MT Newswires", "published_at": "2026-05-05T11:08:21+00:00", "published_display": "05 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Downgrades Esperion Therapeutics to Neutral From Overweight, Adjusts Price Target to $3.16 From $9", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/piper-sandler-downgrades-esperion-therapeutics-112522147.html", "source_name": "MT Newswires", "published_at": "2026-05-04T11:25:22+00:00", "published_display": "04 May 2026 11:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCHIMED to buy Esperion (Nasdaq: ESPR) for $3.16 per share plus CVRs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOOFV5cVd0azRxb1FBdTB3djhFQmJnNmpudU5iME9Ib0lMdEdaclVRNVl4YjIwZ2FDZGFiSkQ1dzdKU1ExeGFuVWo2UVE5VkUwNF9RdEN1TnprY2pzeEVmLWhsMktxOHUzNDJCbE51YWFLOWFGZDlpTzVWNzJtaWx1akpUSTJ0Y2E1YlVpZFZRT2MxZlA2SnNOZU9xVzk1Z0Y4eE1BdHVuNXE1SW1JZWZJSDR1WWo?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc. ($ESPR) President and CEO 2025 Pay Revealed | ESPR Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxORld1QkYxVkN0RkFtanFxcnVWWGxXQzRCdTQxbGJ1cjJ4akMzeVdPbHJUa3BCa203T1BSbUtaUXk2QzBySXp0cUQ0MkloVVBPZE9UM2h4NU5uSjZ4WnFCMzc4cVIwUWtNZG4tZnY2NVVfeWV3SDVMN0lqc1NvNzFVZWFTcEFKb2JqZHUwa3RRRWhFTFF2OElHZ2lmQWlmUjBZcmdWeEJINlRlQmhaZ1lZOGJR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNbzZqNVdldUl4LVI2WUZ6eURnNUFwV2xGbWNTaHl4RHFsVmVkNERfcldxbm56SmpBZHJCVDUxS21WdklTQmo2X244R0FtYTV2NGMtTFRpRExkMW50NU9lU0JMQ3otZndHQThhM0VXZHhfNTRYVjVGTW9jYVRLbVFLUlZtUlZXXzJPV21fbFREQjJ1WnR1UVNSU2NYM3hsOEdKYVhUV3Z3?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA reiterates Esperion Therapeutics stock Underperform rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQWGMxNlIyV3luZUpGWDJPbWlHYzlYVElaT3VzSkJWZHRINTYwMUV0V0FIaldNZEtTakFHQU1RVy1KMmxCZnV1c0Z5LWRlT1J6YlVHZ1NHeWNRMU1rNzlQWl9HQkhxdy1YZVdVd29pY1JFa0dKLTBOREF5dHhfZWFGMnNyLXBKczlzZ0R5VnZDNzd0ZDdMUFY2SmFfQkl6N0xCejlZZGZqcFFwZlM5aVFrZVEwdnhYaDZFb0tkSnNHaDE?oc=5", "source_name": "Investing.com", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breaking News: Massive Guideline NEWS for Esperion Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQZTVueVV6YkIzdWxvcnIwaFRZSkFYTDFNNy15WFhJTzFlOXJfU1g5TlNJdE1rMlMweWstSGtHNlhVd3dNWE9QQUs4NE9jSGFHWHJHR3dXNlQ5R2VJZDZqTVliRVg5cmJxVDlMTFRTckRRdU44bmlfRDN0bHVZYjA2UlJHYlRoS1lrWWluVlAtTVJwNkl5eTAzd2tmU2tmNTJQNllmVlhJZEY1Q003UW1jYklXak45STQ?oc=5", "source_name": "Moomoo", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Esperion Therapeutics Stock Sinking Premarket Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOMW0zVHl4d0RoYTR1S29nUlQ0bFc3cVJ1UElSU3hacEk5blp3T25OOTRqcjJURlpHTU42S1VNRG1ELU5HcGdVeDFkWXB5OG1sOEVTUV9UWTB4LTRGUm5xZUV2NTM4UndaV2kxZWNneWhETlp1eURwcklEWUZRc05QcE10LUhKVGVCMENubHN2UnRQTTlhVDNBUURHWXBkeEd4MTJMWmVWTWpjdVo5XzNnRnVfQkV2NEZ3dkQ1Qnd3OA?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics, Inc. (ESPR) Stock Price Today: $3.19", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE8zd0dNS3dneVNaYU11ZGVPWHdBaG1Tb0pGdHNHNy1QS0ZRQjNTRjRKRXNqdGtVdk4yQ2xiVkJsd3NiZE9WT295a251OHZ6bEdaVEJVMHBmNA?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T00:25:52+00:00", "published_display": "13 Jan 2026 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxNZlZ5eVc5OFpxQWlnYnN4Vk9waEZ1RERsby14SWFDNVJCejdNZzVxU1UzNjRmeERVc25OM3ZkRUhjcGQ2OG5FMGdnem9sTjdtcXZwaWhmajY4a19rT2NpQTVTMFZDUUFsZEwyMlBtY1pwXy1BU21tYnJ5anZmLWFsa0xscEpGd0lFUnhEaFlJVkl4ZXIwTWdhX1VtRUVkWmM0bmtNaWVRYW9nMkpWeHFsMTFQRFJySTFWeGVGWDhsaU1QWjh2Vk9GeFBMc2FvYlpqM1N2alBqbVpmUXN0bkx1dVhBVDBza1RCMGtfb1VySVEzNXJJODlBZDNIQUk5NjBPOTFwUGVxeTRDVTBhSDgyWHJjeXh3c0U?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Esperion Therapeutics (ESPR): Evaluating Valuation After $75 Million Equity Raise and Recent Share Price Volatility", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 83, "total_relevant": 50, "sentiment_summary": {"positive": 9, "negative": 10, "neutral": 31, "score": 47, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 13.2, "count": 24}, {"event": "deals", "label": "Deals and strategy", "weight": 7.15, "count": 13}, {"event": "earnings", "label": "Earnings", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 3.18, "latest_week": "2026-07-10", "one_week_move": 0.6, "four_week_move": 1.0, "twelve_week_move": 55.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.618964, "market_dynamics_buy_signal": false, "relative_strength": -5.179393, "fair_value_gap": 45.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 51.6605, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.6% over one week, +1.0% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 16}, {"label": "TradingView", "count": 8}, {"label": "www.marketscreener.com", "count": 4}, {"label": "Stocktwits", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Market source", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Deals and strategy", "count": 13}, {"label": "Earnings", "count": 6}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "47/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.6% over one week, +1.0% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake"}], "updated_at": "2026-07-15T23:34:03.822474+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}